Document:

Description of Certain Compensatory Arrangements

 Exhibit 10.20 
 Description of Certain Compensatory Arrangements 
 Executive Compensation 
 Varian Medical Systems, Inc. (the “Company”) does not have a written employment agreement with any of its named executive officers (determined
by reference to the Company’s 2008 proxy statement dated December 28, 2007). On November 14, 2008, the Compensation and Management Development Committee (the “Compensation Committee”) of the Company’s Board of Directors
(the “Board”) approved new compensation arrangements for the Company’s Principal Executive Officer, Principal Financial Officer, and the other named executive officers. Set forth below are the current annual base salaries and the base
salaries that will go into effect on December 27, 2008: 
  

					
	 Name
	  	Current
Base Salary	  	Base Salary as
of 12/27/08
	 Timothy E. Guertin,
       Corporate President and Chief Executive Officer
	  	$835,000	  	$875,000
	 Elisha W. Finney,
       Corporate Senior Vice President, Finance and Chief Financial Officer
	  	$495,000	  	$520,000
	 Dow R. Wilson,
       Corporate Executive Vice President and President, Oncology Systems
	  	$580,000	  	$606,000
	 Robert H. Kluge,
       Corporate Senior Vice President and President, X-ray Products
	  	$392,000	  	$412,000
	 John W. Kuo,
       Corporate Vice President, General Counsel and Corporate Secretary
	  	$345,000	  	$362,000

 On November 14, 2008, the Compensation and Management Development Committee also set the
performance goals for fiscal year 2009 under the Company’s Management Incentive Plan (“MIP”) for the named executive officers and certain other executives. In the case of Timothy E. Guertin, Elisha W. Finney and John W. Kuo, payments
under the MIP will be based 50% on a percentage growth of earnings before interest and taxes (“EBIT”) for the Company as a whole, 25% on growth in revenue for the Company and 25% on growth in net orders for the Company as a whole. In the
case of Dow R. Wilson, payment under the MIP will be based 25% on the percentage growth in EBIT for the Company as a whole, 12.5% on growth in revenue for the Company as a whole, 12.5% on growth in net orders for the Company as a whole, 25% on the
percentage growth in EBIT for the Oncology Systems business segment, 12.5% on growth in revenue for the Oncology Systems business segment and 12.5% on growth in net orders for the Oncology Systems business segment. In the case of Robert H. Kluge,
payment under the MIP will be based 25% on the percentage growth in EBIT for the Company as a whole, 12.5% on growth in revenue for the Company as a whole, 12.5% on growth in net orders for the Company as a whole, 25% on the percentage growth in
EBIT for the X-ray Products business segment, 12.5% on growth in revenues for the X-ray Products business segment and 12.5% on growth in net orders for the X-ray Products business segment. Payment under the MIP may vary from $0 to 200% of base
salary based upon achievement under these performance goals. 

 Set forth below are the percentages of base salary each of these individuals would receive if the target
and maximum levels under the MIP are achieved: 
  

						
	 Name
	  	Target	 	 	Maximum
			
	 Timothy E. Guertin
	  	110	%	 	200%
	 Elisha W. Finney
	  	80	%	 	160%
	 Dow R. Wilson
	  	80	%	 	160%
	 Robert H. Kluge
	  	60	%	 	120%
	 John W. Kuo
	  	60	%	 	120%

 These executive officers have also been extended certain perquisites by the Compensation
Committee, such as use of a leased automobile under the Company’s Executive Car Program. Under the Executive Car Program, the Company provides a leased vehicle costing up to $82,000 for the Chief Executive Officer and leased vehicles costing up
to $68,000 for the other named executive officers. Insurance, maintenance expenses and fuel costs are also included in the Executive Car Program. Participants have an option to purchase the car at the end of its three-year lease period or upon
retirement at the lower of its depreciated book value or its fair market value (based on the Kelley Blue Book Auto Market Report wholesale value). 
 The Company does not permit its executives to use the Company’s fractionally owned aircraft for purely personal trips. However, the Company allows and includes in an executive’s compensation aircraft use attributable to permitted
spousal use of the fractionally owned aircraft for business purposes and spousal travel on commercial airplanes deemed valuable and appropriate for business purposes. The amount of compensation for permitted spousal use of the
Company’s fractionally owned aircraft is equal to the greater of: (a) the incremental cost to us of the usage by the spouse, and (b) the price of a first-class commercial airline ticket for the same trip. 
 The Company reimburses executive officers and non-executive officers for financial planning, estate planning, tax planning, tax return preparation and
financial counseling services (to a maximum of $6,500 per year and unlimited for the Chief Executive Officer). The Company also reimburses certain individuals, including all executive officers and non-executive officers, for annual medical
examinations (up to a maximum of $4,000 per year). Beginning on January 1, 2006, reimbursement for personal taxes paid on all perquisites, with the exception of leased vehicles, was discontinued. The elimination of reimbursement for personal
taxes associated with leased vehicles is being phased-in as each applicable lease expires. 
 Additionally, for the benefit of the
executives, the Company also provides a Company supplemental contribution match representing retirement contributions which could not be contributed to the executives’ qualified retirement accounts due to Internal Revenue Code limitations. The
Company also permits executives to participate in the Company’s Deferred Compensation Plan and in compensation and benefit programs generally available to all other U.S. employees, such as the Company’s Employee Incentive Plan, Employee
Stock Purchase Plan, 401(k) Retirement Program and supplemental life and disability insurance programs. 
 Mr. Wilson’s
employment is governed by an offer letter that provides for certain additional compensation. Please refer to Exhibits 10.18 and 10.19 of the Company’s Annual Report on Form 10-K for the fiscal year ended September 26, 2008. 

 Compensation of Directors 
 Annual Cash Compensation. Each non-employee director receives an annual retainer of $45,000, except that the lead director receives an annual
retainer of $60,000. The chairs of the Compensation and Management Development Committee and the Nominating and Corporate Governance Committee also receive an additional $10,000 annual retainer for serving in these positions, and the chair of the
Audit Committee receives an additional $15,000. Each non-employee director also receives $2,000 for each Board meeting attended ($1,000 if the Board meeting was an in-person meeting and the director attended by telephone or video conference), and
$1,500 for each committee meeting attended ($750 if the committee meeting was an in-person meeting and the director attended by telephone or video conference). Directors who are employees receive no compensation for their services as directors. All
directors, however, receive reimbursement for out-of-pocket expenses of the directors’ and the directors’ spouses (including tax reimbursement for spousal expenses) associated with attending Board and committee meetings and for expenses
related to directors’ continuing education programs. Until February 15, 2008, directors could convert their cash compensation into options to purchase shares of the Company’s common stock at the rate of $1 cash to $4 of stock options,
at an exercise price equal to the fair market value of the common stock on the grant date, which is the date that the cash compensation otherwise would have been paid. Under the Company’s equity compensation plans, the fair market value is
equal to the closing price (i.e., the closing price) of the Company’s common stock on the date of grant, which is the date that the foregone cash compensation otherwise would have been paid. These options are immediately exercisable and
expire seven years after the grant date unless terminated earlier. Since February 15, 2008, non-employee directors may no longer elect to receive options for shares of the Company’s common stock in lieu of cash compensation, but may elect
to receive such compensation as full-value shares of the Company’s common stock, at a value equal to the fair market value of the Company’s common stock on the date that the foregone cash compensation otherwise would have been paid.
Directors may alternatively elect to defer their retainer and/or meeting fees under the Company’s Deferred Compensation Plan. 
 Equity Compensation. Effective February 15, 2008, each continuing non-employee director receives an annual grant of non-qualified stock options to purchase 5,000 shares of common stock and an annual grant of Deferred Stock Units
having a fair market value on the date of grant of $100,000, based on the fair market value (i.e., the closing price) of our common stock on the date of grant. New non-employee directors do not receive initial grants of stock options or
Deferred Stock Units. 
 Compensation for Levy as a Non-Executive Employee 
 In his role as a non-executive employee of the Company, Dr. Levy receives the following compensation, effective as of the close of business on
February 15, 2008: 
  

	 	•	 	 base salary of $160,000; 

	 	•	 	 provision of a leased office space at a fair market value; 

	 	•	 	 provision of a part-time administrator; and 

	 	•	 	 eligibility for the Corporation’s non-executive employee health and welfare benefit plans, subject to his election and contributions towards those benefit
plans. 

 Dr. Levy is not eligible to participate in the Company’s Management Incentive Plan and in any executive
perquisite programs, including the Executive Car Program and reimbursement for executive physicals. He is also not eligible for equity awards, paid personal leave accrual or for any supplemental retirement contributions in excess of the
Company’s matching contributions under the Varian Medical Systems, Inc. Retirement Plan (the Company’s 401(k) Plan). 

 In his role as a non-executive employee of the Company (and in addition to his responsibilities as
Chairman of the Board), Dr. Levy provides on-going advice and counsel to the management of the Company on strategic business and technological matters, and has involvement with investor groups and key customers.Amdmt No. 2 to Registrant's Second Amended and Restated 2005 Omnibus Stock Plan

 Exhibit 10.23 
 AMENDMENT NO. 2 
 TO THE 
 VARIAN MEDICAL SYSTEMS, INC. 
 SECOND AMENDED AND RESTATED 
 2005 OMNIBUS STOCK PLAN 
 Varian
Medical Systems, Inc. having previously established the Varian Medical Systems, Inc. Second Amended and Restated 2005 Omnibus Stock Plan (the “Plan”), hereby amends the Plan, effective as of August 8, 2008 as follows: 
 The last sentence in Section 2.49 is hereby amended in its entirely to read as follows: 
 “Notwithstanding the foregoing, to the extent that “Termination of Service” is used to establish a payment event with
respect to any Award subject to section 409A of the Code, “Termination of Service” shall have the same meaning as “separation from service” as that term is defined in section 409A of the Code and the applicable guidance issued by
the Secretary of the Treasury thereunder.” 
 IN WITNESS WHEREOF, Varian Medical Systems, Inc., by its duly authorized officer, has
executed the Plan on the date indicated below. 
  

							
		 		 	Varian Medical Systems, Inc.
				
	Dated: August 8, 2008	 		 	By:	 	/s/ John W. Kuo
		 		 		 	John W. Kuo
		 		 		 	 Corporate Vice President,
 General
Counsel & Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}]]